SAN ANTONIO — A U.S. drug maker has made a deal with a Swiss company to manufacture and sell a new osteoporosis treatment in North America.
Mission Pharmacal announced Tuesday a patent and technology licensing agreement with Freienbach, Switzerland-based EffRx Pharmaceuticals for Binosto (alendronate sodium) effervescent tablets in the United States and Canada. Financial terms were not disclosed.
